当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases
Drug Discovery Today ( IF 6.5 ) Pub Date : 2021-07-03 , DOI: 10.1016/j.drudis.2021.06.010
Frédéric De Ceuninck 1 , Fanny Duguet 1 , Audrey Aussy 2 , Laurence Laigle 2 , Philippe Moingeon 3
Affiliation  

Interferon (IFN)-α has emerged as a major therapeutic target for several autoimmune rheumatic diseases. In this review, we focus on clinical and preclinical advances in anti-IFN-α treatments in systemic lupus erythematosus (SLE), primary Sjögren syndrome (pSS), systemic sclerosis (SSc), and dermatomyositis (DM), for which a high medical need persists. Promising achievements were obtained following direct IFN-α neutralization, targeting its production through the cytosolic nucleic acid sensor pathways or by blocking its downstream effects through the type I IFN receptor. We further focus on molecular profiling and data integration approaches as crucial steps to select patients most likely to benefit from anti-IFN-α therapies within a precision medicine approach.



中文翻译:

IFN-α:多种自身免疫性风湿病的关键治疗靶点

干扰素 (IFN)-α 已成为几种自身免疫性风湿性疾病的主要治疗靶点。在这篇综述中,我们关注抗 IFN-α 治疗系统性红斑狼疮 (SLE)、原发性干燥综合征 (pSS)、系统性硬化症 (SSc) 和皮肌炎 (DM) 的临床和临床前进展。需求持续存在。在直接中和 IFN-α 后获得了有希望的成就,通过细胞溶质核酸传感器途径靶向其产生或通过 I 型 IFN 受体阻断其下游效应。我们进一步关注分子分析和数据整合方法,作为在精准医疗方法中选择最有可能从抗 IFN-α 疗法中受益的患者的关键步骤。

更新日期:2021-07-03
down
wechat
bug